Summary
- Profile Type
- Technology offer
- POD Reference
- TOES20230628019
- Term of Validity
- 28 June 2023 - 27 June 2025
- Company's Country
- Spain
- Type of partnership
- Research and development cooperation agreement
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A health research institute in Spain has developed a method to detect and stage COVID patients by detecting distinctive Redox features in a drop of whole blood. The methodology of the technique is cheaper than those in the market, with similar performance and reduced false negatives due to sampling. Usage requires no professional training. It is ideal for Covid staging in primary care. A biomedical company is sought to develop it further and distribute either the device or the reagent kit.
- Full Description
- This method was developed at the Health Research Institute of Asturias (ISPA) in Spain by the BioxMet group, which bases their research on the study of redox metabolism in several diseases. The method allows to detect and stage COVID patients by detecting distinctive Redox features in a drop of whole blood. This is relevant as COVID severity relies on a systemic inflammatory burst. This method provides information not only about COVID infection status but also about the stage of the disease. The method is based on spectrophotometric features, spectrophotometers allow repeated measurements and are already present in several laboratories. Also, small spectrophotometers are easy to produce and are relatively cheap to acquire. A system or kit based on this system would be cheaper than those in the market, with similar performance and reduced false negatives due to sampling as the sample collection requires no professional training. The analysis and interpretation of the data also has the potential to be used by non-health-care professionals. It is ideal for COVID detection and staging in primary care and might be very useful for low-income countries.
- Advantages and Innovations
- This technology allows to detection and staging of COVID in short period of time. Potentially would allow to detect and stage COVID with a blood drop on a single device, as it is based on spectrophotometric absoption at particular wavelengths. This makes the method simple, robust, very reproducible, sensitive, fast and very cheap. It would allow applications in work-places, primary care and low-income countries. It is to our knowledge the only redox-based COVID diagnosis system.
- Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
- Biotech or Biomedical company to develop further and distribute either the device or the reagent kit.
- Type and Size of Partner
- Big company
- R&D Institution
- University
- SME <=10
- SME 50 - 249
- SME 11-49
- Type of partnership
- Research and development cooperation agreement
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06002007 - In vitro Testing, Trials
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 05001001 - Diagnostic services
- 05001002 - In-vitro diagnostics
- Sector Groups Involved
- Health
- Targeted countries
- All countries